Sibel joined Adelis in 2022 where she focuses on Healthcare & Life Sciences investments. Sibel has been a board member at BBI Solutions (UK), Tempus Labs (US), and Mission Bio (US), and is currently on the board of SSI Diagnostica (DK).

Prior to joining Adelis, Sibel worked as a Principal at Novo Holdings from 2016 to 2022 where she focused on life science and healthcare investments in Europe and the US. Sibel started her professional career at Bain & Company, where she worked primarily with private equity due diligences and corporate strategy for leading Nordic companies.

Education: MSc, Finance & Strategic Management, Copenhagen Business School / CEIBS in Shanghai. BSc. International Business & Politics, Copenhagen Business School.